Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04113083
Other study ID # TR-CTX-002
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date October 19, 2019
Est. completion date June 10, 2022

Study information

Verified date June 2022
Source TRPHARM
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The prevalence of CTX in our country is estimated to be 1 / 50.000. The aim of this study is to screen more volunteers by conducting a larger screening from neurology and pediatric metabolism clinics in Turkey. This observational study was designed retrospectively and prospectively in two stages. In the retrospective section, the patient database and / or patient files will be screened in the neurology and pediatric metabolism clinics and the patients aged 40 and below in the neurology clinics with at least two of the following will be enrolled to the study: - Ataxia and / or spasticity - Bilateral cataract (except senile cataract) - Intellectual limitation - Non-enhancing hyperintensity on T2 sections in MR imaging of dentate nuclei - Autosomal recessive transition pattern. (Ex: Relative Marriage) In the pediatric metabolism centers, cases suspected of CTX and planned to apply the Mignarri Index according to the investigator's opinion will be identified.


Recruitment information / eligibility

Status Terminated
Enrollment 22
Est. completion date June 10, 2022
Est. primary completion date March 16, 2022
Accepts healthy volunteers No
Gender All
Age group N/A to 40 Years
Eligibility Inclusion Criteria: I-1. Giving written informed consent I-2. Patients in neurology clinics should have been identified with at least two of the following: - Ataxia and / or spasticity - Bilateral cataract (except senile cataract) - Intellectual limitation - Nonintensitive hyperintensity in T2 sections on MRI of the dentate nucleus - Forming an autosomal recessive transition pattern. (Ex: Relative Marriage) I-3. In the pediatric metabolism centers, cases suspected of CTX and planned to apply the Mignarri Index according to the investigator's opinion. I-4. On the day the patient signed the Informed Consent Form, the patient did not get older than 41 years of age (subjects aged 40 and under will be included in the study) Exclusion Criteria: E-1. The patient's ataxia and / or spasticity, cataract, intellectual limitation, and non-contrasted hyperintensity of T2 sections in MR imaging of dentate nuclei with typical MRI findings are due to a known cause other than CTX or other underlying disease. E-2. The patient has participated in an interventional clinical study in the last 30 days, E-3. The patient and / or his / her legal representative does not give consent to participate in the study, E-4. In the opinion of the investigator, the patient is not able to fulfill the working requirements appropriately, E-5. Pregnancy and / or lactation E-6. If the patient was 41 years old when included in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Blood sampling for cholestanol analysis
Blood sampling will be performed by Düzen Laboratories group for cholestanol

Locations

Country Name City State
Turkey Çukurova University Medical Faculty Deparment of Metabolism Adana
Turkey Çukurova University Medical Faculty Department of Neurology Adana
Turkey Ankara Child and Heamatology Hospital Deparment of Metabolism Ankara
Turkey Ankara City Hospital Ankara
Turkey Ankara Diskapi Yildirim Beyazit Research and Training Hospital Clinic of Neurology Ankara
Turkey Gazi University Medical Faculty Department of Pediatric Metabolism Ankara
Turkey Hacettepe University Medical Faculty Deparment of Metabolism Ankara
Turkey Hacettepe University Medical Faculty Department of Neurology Ankara
Turkey Osmangazi University Medical Faculty Department of Neurology Eskisehir
Turkey Osmangazi University Medical Faculty Department of Pediatric Metabolism Eskisehir
Turkey Bezmi Alem Vakif University Medical Faculty Department of Neurology Istanbul
Turkey Hamidiye Sisli Etfal Research and Training Hospital Clinic of Neurology Istanbul
Turkey Hamidiye Sisli Etfal Research and Training Hospital Clinic of Pediatric Metabolism Istanbul
Turkey Istanbul University Cerrahpasa Medical Faculty Department of Neurology Istanbul
Turkey Istanbul University Cerrahpasa Medical Faculty Department of Pediatric Metabolism Istanbul
Turkey Istanbul University Istanbul Medical Faculty Department of Neurology Istanbul
Turkey Istanbul University Istanbul Medical Faculty Department of Pediatric Metabolism Istanbul
Turkey Kanuni Sultan Suleyman Research and Training Hospital Clinic of Pediatric Metabolism Istanbul
Turkey Medeniyet University Göztepe Research and Training Hospital Clinic of Neurology Istanbul
Turkey Mersin City Hospital Department of Metabolism Mersin
Turkey Mersin University Medical Faculty Department of Neurology Mersin
Turkey Cumhuriyet University Medical Faculty Department of Neurology Sivas

Sponsors (3)

Lead Sponsor Collaborator
TRPHARM Düzen Laboratories Group, Klinar CRO

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients with CTX possibility in Neurology Clinics - Proportion of patients aged 40 years or younger with at least two of the following (2) in patients with a cholestanol test threshold (3.75 mg / mL) in neurology clinics:
Ataxia and / or spasticity
Bilateral cataract (except senile cataract)
Intellectual limitation
Nonintensitive hyperintensity in T2 sections on MRI of the dentate nucleus
Forming an autosomal recessive transition pattern. (Ex: Relative Marriage)
3 years
Primary Proportion of patients with CTX possibility in Pediatric Metabolism Clinics - Proportion of cases above the cholestanol test threshold (3.75 mg / mL) in pediatric metabolism centers 3 years
Secondary Total of Mignarri Suspicion Index (SI) Mignarri is a suspicion index, composed of weight-ed scores assigned to indicators such as family history and common systemic and neurological features. The indicators were classified as very strong (score 100), strong (50) or moderate (25). The suspicion index will be applied to study population. Early systemic signs such as catamct, diarrhea and neonatal cholestatic jaundice were considered strong indica- tors, together with neurological features such as intellectual impairment, psychiatric disturbances, ataxia, spastic paraparesis and dentate nuclei abnormalities at MRI. Tendon xanthomas were regarded as very strong indicators, as was an affected sibling. A total score 100 warranted serum cholestanol assessment. Elevated cholestanol or a total score 200, with one very strong or four strong indicators, warranted CYP27Al gene analysis. (Reference: Mignarri et al. J Inherit Metab Dis (2014) 37:421-429)
-and physical examination results for patients with high cholestanol levels
3 Years
Secondary Cholestanol Levels - Cholestanol levels for patients with high cholestanol levels 3 Years
Secondary Patient demographics For all screened patients:
• Demographic data
3 Years
Secondary CTX Family History For all screened patients:
• CTX family history
3 Years
Secondary Presence of consangunious marriage For all screened patients:
• Presence of consanguineous marriage
3 Years
Secondary Frequency of the systemic findings For all screened patients:
• Frequency of the following systemic findings:
Tendon xanthomas
Chronic diarrhea
Prolonged neonatal jaundice
Early osteoporosis
3 Years
Secondary Frequency of the neurologic findings For all screened patients:
• Frequency of the following neurological symptoms:
Cerebellar ataxia
Spastic paraparesis
Blateral cataract (except senile cataract)
Non-enhancing hyperintensity on T2 sections in MR imaging of dentate nuclei
Intellectual disability
Psychiatric disorders
Epilepsy
Parkinson's
Polyneuropathy
3 Years